Key Highlights

  • AdaptHealth shares closed down 7.00% on August 6 at $6.05, hitting fresh 52-week lows
  • RBC cut its price target to $8 from $15, and UBS cut its target to $14
  • The company sharply reduced full-year 2026 EBITDA guidance to $490 to $520 million, down from a prior $680 to $730 million
  • AdaptHealth posted 12.7% revenue growth despite the guidance cut
  • The company agreed to sell its Diabetes Health unit for $235 million to help pay down debt

What Happened

AdaptHealth (NASDAQ:AHCO) shares closed down 7.00% on August 6 at $6.05, tumbling to fresh 52-week lows following a wave of steep analyst price target cuts in the wake of Tuesday's disappointing Q2 report. AdaptHealth is a national leader in patient-centered, healthcare-at-home solutions, providing home medical equipment, medical supplies, and related services across the United States, operating through core segments including Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home.

RBC slashed its price target to $8 from $15, while UBS cut its target to $14, both reflecting bearish ratings, as analysts digest the company's sharply reduced full-year 2026 EBITDA guidance of $490 to $520 million, down from a prior range of $680 to $730 million, driven by a costly West Coast capitated contract and a manufacturer price increase.

Diabetes Health Sale Announced

The stock's continued slide reflects lingering investor concern over margin pressure and execution risk, even as AdaptHealth posted 12.7% revenue growth and agreed to sell its Diabetes Health unit for $235 million to help pay down debt.

Conclusion

AdaptHealth's close down 7.00% on August 6, at fresh 52-week lows, reflects investor concern over the sharply reduced EBITDA guidance and margin pressure, even as the company continues to post solid revenue growth and moves to streamline its business through the Diabetes Health divestiture.

This article is for informational purposes only and does not constitute financial or investment advice. Readers should conduct their own research or consult a financial professional before making investment decisions.